Could a nasal spray flu shot at home beat the needle?

NCT ID NCT07739719

Not yet recruiting Prevention Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether offering a needle-free flu vaccine (FLUMIST) for self-administration at home, picked up from a pharmacy, increases flu vaccination rates compared to usual care. Households with children aged 2 to 17 in Burlington, Ontario, are randomly assigned to either receive the home vaccine option or follow standard flu season choices. The goal is to see if this convenient approach encourages more people to get vaccinated against the flu.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FLUMIST (live attenuated influenza vaccine) given as a nasal spray
What this could lead to: If this works, it could make flu vaccination easier and more accessible, potentially increasing uptake and reducing flu-related hospitalizations.
What could go wrong: The trial is limited to one region and may not reflect broader populations. Self-administration could lead to improper use or reduced vaccine effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA (HEALTHY VOLUNTEERS)

Contacts and locations

Locations

McMaster University

Hamilton, Ontario, L8S 4K1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.